相关实验视频

Updated: May 27, 2025

Rescue of Recombinant Newcastle Disease Virus from cDNA

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

复合肠炎病毒载体疫苗研究的现状

Wen-Feng Jia¹, An-Ping Wang¹, Zhi Wu¹

¹Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou, China.

Frontiers in veterinary science

|February 20, 2025

概括

肠炎病毒 (DEV) 是一个有希望的活体载体,可用于开发多价值禽疫苗. 基因进步使得创建重组DEV疫苗能够有效地对抗多种病原体.

科学领域:

病毒学病毒学
免疫学免疫学免疫学
疫苗学疫苗学疫苗学

背景情况:

肠炎病毒 (DEV) 是一种具有大型基因组的α-疹病毒,具有适合基因改造的非必需区域.
DEV的特点使其成为可行的候选人,用于作为疫苗开发中的活病毒载体.

研究的目的:

审查使用DEV作为载体的复合疫苗的研究进展.
提供关于DEV作为疫苗载体的生物特性,优势和局限性的见解.

主要方法:

对DEV基因组的基因改造技术的概述.
讨论构建重组DEV活载体疫苗的平台.
对影响重组DEV疫苗疗效的因素的分析.

主要成果:

再组合DEV活载体疫苗的成功构建是通过分子生物学方面的进步来实现的.
这些重组疫苗证明了对DEV和其他病原体的有效性,突出了它们的潜力.

结论:

重组DEV载体对于开发新型多价值禽疫苗至关重要.
基于DEV的疫苗的进一步研究和应用对于推进家禽健康和疾病控制至关重要.

关键词:

禽类疫苗的使用情况子肠炎病毒的病毒遗传修饰是一种基因改造.免疫保护的有效性免疫保护的有效性再组合载体疫苗疫苗的使用.水鸟传染病感染性疾病

更多相关视频

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

相关概念视频

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.